Lilly, Novo Nordisk and Sanofi assured customers that supplies of insulin and other diabetes medications will be stable throughout the COVID-19 pandemic as fears of drug shortages rise. The three major insulin manufacturers in the US also offer options for patients with diabetes who cannot afford their insulin, but advised patients to prepare for a rise in demand and possible delays in filling prescriptions in the coming days.
No shortage of insulin supplies, top manufacturers say
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.